Related Experiment Video
Updated: Aug 3, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms
Rohit Thummalapalli1, Salomon Tendler1, Joanne F Chou2
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Purpose:
Delta-like ligand 3 (DLL3) is an emerging target across neuroendocrine cancers, but remains underexplored in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs), including poorly differentiated gastroenteropancreatic neuroendocrine carcinomas (GEP NECs) and well-differentiated neuroendocrine tumors (NETs). We aimed to define the landscape of DLL3 expression and feasibility of DLL3-targeted imaging in this population.
Patients And Methods:
We completed DLL3 immunohistochemistry (IHC) on 379 tumor samples from patients with GEP NENs, analyzing associations between DLL3 IHC positivity, clinicopathologic features, and outcomes. [89Zr]Zr-DFO-SC16.56 DLL3 immuno-positron emission tomography-computed tomography (immunoPET-CT) imaging was performed in six patients with DLL3 IHC-positive advanced GEP NENs.
Results:
Among GEP NECs, DLL3 expression was identified in 55/78 (71%) tumors, was enriched for small cell histology, and did not demonstrate prognostic significance. Among well-differentiated gastroenteropancreatic neuroendocrine tumors, DLL3 expression was identified in 5/235 (2%) of grade 1-2 and 25/66 (40%) grade 3 (G3) tumors, most commonly G3 pancreatic NETs (PanNETs; 22/52, 43%), with univariate analysis revealing increased mortality risk among patients with DLL3-positive advanced G3 PanNETs (hazard ratio 3.27 [95% CI, 1.09 to 9.78]). Between May 28, 2024, and February 10, 2025, six patients with DLL3 IHC-positive GEP NENs underwent [89Zr]Zr-DFO-SC16.56 immunoPET-CT imaging, which delineated DLL3-avid tumor lesions in five of six patients (two of two GEP NECs, three of four G3 PanNETs). Tumor-specific uptake of [89Zr]Zr-DFO-SC16.56 varied between patients, with maximum standard uptake values ranging from 7.4 to 36.7, with four of six cases demonstrating DLL3 avidity in ≥50% of tumor lesions.
Conclusion:
DLL3 is expressed on a majority of GEP NECs and on a subset of high-grade PanNETs marked by poor outcomes. Functional imaging suggests DLL3 as a promising therapeutic target in both GEP NECs and high-grade PanNETs.
Insights
Delta-like ligand 3 (DLL3) is expressed in most gastroenteropancreatic neuroendocrine carcinomas (GEP NECs) and some high-grade pancreatic neuroendocrine tumors (PanNETs). DLL3-targeted imaging shows promise for these neuroendocrine cancer types.
Area of Science:
- Oncology
- Molecular Imaging
- Cancer Biology
Background:
- Delta-like ligand 3 (DLL3) is a novel target in neuroendocrine cancers.
- DLL3 expression is not well-characterized in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs).
Purpose of the Study:
- To investigate DLL3 expression across gastroenteropancreatic neuroendocrine neoplasms (GEP NENs).
- To assess the feasibility of DLL3-targeted immuno-PET-CT imaging in GEP NENs.
Main Methods:
- DLL3 immunohistochemistry (IHC) was performed on 379 GEP NEN tumor samples.
- [89Zr]Zr-DFO-SC16.56 immuno-PET-CT imaging was conducted in six patients with DLL3-positive GEP NENs.
Main Results:
- DLL3 expression was found in 71% of GEP neuroendocrine carcinomas (NECs) and 40% of grade 3 gastroenteropancreatic neuroendocrine tumors (GEP NETs).
- DLL3 positivity correlated with increased mortality in advanced G3 PanNETs.
- Immuno-PET-CT successfully visualized DLL3-avid lesions in 5/6 patients, including GEP NECs and G3 PanNETs.
Conclusions:
- DLL3 is expressed in a majority of GEP NECs and a subset of high-grade PanNETs.
- DLL3-targeted imaging demonstrates potential for GEP NECs and high-grade PanNETs.
- DLL3 represents a promising therapeutic target for these GEP NEN subtypes.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
09:06Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
Published on: February 3, 2023
Related Concept Videos
Hormonal Regulation
IP3/DAG Signaling Pathway
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Regulation of the Digestive System
The effectors in this regulation system are glands and smooth muscles. Activation of these...
Hormones Secreted by the Stomach
Each of these hormones secreted by different enteroendocrine cells plays a unique role in digestion. Here are a few examples:
Intestinal Phase of Digestion
The arrival of the chyme in the small intestine distends the duodenum, which triggers the enterogastric reflex. This distension...